137 related articles for article (PubMed ID: 32843426)
21. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
Coffee EM; Faber AC; Roper J; Sinnamon MJ; Goel G; Keung L; Wang WV; Vecchione L; de Vriendt V; Weinstein BJ; Bronson RT; Tejpar S; Xavier RJ; Engelman JA; Martin ES; Hung KE
Clin Cancer Res; 2013 May; 19(10):2688-98. PubMed ID: 23549875
[TBL] [Abstract][Full Text] [Related]
22. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
Wang N; Wen J; Ren W; Wu Y; Deng C
Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
26. Sustained Tumor Control With MAPK Inhibition in
Berzero G; Bellu L; Baldini C; Ducray F; Guyon D; Eoli M; Silvani A; Dehais C; Idbaih A; Younan N; Nguyen-Them L; Gaillard S; Pasqualetti F; Lepage-Seydoux C; Sekkate S; Tresca P; Kas A; Gratieux J; Ammari S; Saragoussi E; Savatovsky J; Delattre JY; Hoang-Xuan K; Meyronet D; Villa C; Bielle F; Sanson M; Touat M; Di Stefano AL
Neurology; 2021 Aug; 97(7):e673-e683. PubMed ID: 34088874
[TBL] [Abstract][Full Text] [Related]
27. Targeting BRAF in pediatric brain tumors.
Kieran MW
Am Soc Clin Oncol Educ Book; 2014; ():e436-40. PubMed ID: 24857135
[TBL] [Abstract][Full Text] [Related]
28. Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.
Rittler D; Molnár E; Baranyi M; Garay T; Hegedűs L; Aigner C; Tóvári J; Tímár J; Hegedűs B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081092
[TBL] [Abstract][Full Text] [Related]
29.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
30. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.
Marks AM; Bindra RS; DiLuna ML; Huttner A; Jairam V; Kahle KT; Kieran MW
Pediatr Blood Cancer; 2018 May; 65(5):e26969. PubMed ID: 29380516
[TBL] [Abstract][Full Text] [Related]
31. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
Carroll MJ; Parent CR; Page D; Kreeger PK
BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
[TBL] [Abstract][Full Text] [Related]
32. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
Yukimoto R; Nishida N; Hata T; Fujino S; Ogino T; Miyoshi N; Takahashi H; Uemura M; Satoh T; Hirofumi Y; Mizushima T; Doki Y; Eguchi H
Cancer Sci; 2021 Jul; 112(7):2884-2894. PubMed ID: 33934428
[TBL] [Abstract][Full Text] [Related]
33. USP18 enhances the resistance of BRAF-mutated melanoma cells to vemurafenib by stabilizing cGAS expression to induce cell autophagy.
Ma ZR; Xiong QW; Cai SZ; Ding LT; Yin CH; Xia HL; Liu W; Dai S; Zhang Y; Zhu ZH; Huang ZJ; Wang Q; Yan XM
Int Immunopharmacol; 2023 Sep; 122():110617. PubMed ID: 37478666
[TBL] [Abstract][Full Text] [Related]
34. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
[TBL] [Abstract][Full Text] [Related]
35. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
37. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
38. HI-511 overcomes melanoma drug resistance
Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z
Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956
[No Abstract] [Full Text] [Related]
39. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors.
Mulcahy Levy JM; Zahedi S; Griesinger AM; Morin A; Davies KD; Aisner DL; Kleinschmidt-DeMasters BK; Fitzwalter BE; Goodall ML; Thorburn J; Amani V; Donson AM; Birks DK; Mirsky DM; Hankinson TC; Handler MH; Green AL; Vibhakar R; Foreman NK; Thorburn A
Elife; 2017 Jan; 6():. PubMed ID: 28094001
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
